Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
To read the full story
Related Article
- “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
August 14, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
- Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
ORGANIZATION
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
- Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
- Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
- JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
- New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…